VRK2 Antibody

What are the validated applications for VRK2 antibodies in research settings?

VRK2 antibodies have been extensively validated for multiple research applications with specific recommendations for optimal performance:

For reliable results, it is essential to titrate antibody concentrations for each specific experimental system as detection efficiency may vary based on sample types and protein expression levels . When using IHC, antigen retrieval with TE buffer (pH 9.0) or alternatively with citrate buffer (pH 6.0) is recommended for optimal epitope exposure .

What is the expected molecular weight of VRK2 protein in Western blot analysis?

When using VRK2 antibodies for Western blot analysis, researchers should note the following specifications:

• Calculated molecular weight: 58 kDa (508 amino acids)

• Observed molecular weight: Typically between 50-58 kDa depending on the antibody and cell/tissue type

This discrepancy between calculated and observed molecular weights is important to consider when interpreting results. The variation may be attributed to:

• Post-translational modifications affecting protein migration

• Detection of different VRK2 isoforms (VRK2A vs. VRK2B)

• Tissue-specific processing of the protein

When validating a new VRK2 antibody, comparison with positive controls such as lysates from K-562, U2OS, or HepG2 cells is strongly recommended .

How can I validate the specificity of a VRK2 antibody?

Thorough validation of VRK2 antibody specificity is critical for reliable experimental outcomes. A comprehensive validation strategy should include:

• Knockout/knockdown controls: Compare detection between wild-type and VRK2 knockout/knockdown samples. Published studies demonstrate significantly reduced signal in VRK2-deficient cells (Vrk2 -/- MLFs and BMDMs) .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific antibodies will show diminished signal when blocked with their immunogen .

• Cross-reactivity assessment: Test antibody performance across multiple species if working with non-human models. Available antibodies show varying reactivity profiles:

  • Human-only reactive

  • Human/mouse/rat reactive

  • Human/mouse reactive

• Multiple antibody correlation: Compare results using different antibodies targeting distinct VRK2 epitopes to confirm consistent detection patterns .

How can VRK2 antibodies be used to differentiate between VRK2 isoforms?

VRK2 gene produces at least two main splice variants (VRK2A and VRK2B) with distinct subcellular localizations and functions . Differentiating between these isoforms requires specialized strategies:

• Epitope selection: Use antibodies that target regions either common to both isoforms or specific to one variant. The VRK2A isoform contains a C-terminal transmembrane domain absent in VRK2B .

• Molecular weight discrimination: VRK2A is the full-length protein (~58 kDa), while VRK2B is slightly smaller due to alternative splicing .

• Subcellular fractionation: Combine with Western blotting to distinguish isoforms based on their distinct localization patterns:

  • VRK2A localizes primarily to the endoplasmic reticulum and mitochondrial membranes

  • VRK2B is predominantly found in the nucleus and cytoplasm

For functional studies, it is essential to verify which isoform(s) your antibody detects to accurately interpret results related to specific cellular processes .

What approaches are recommended for studying VRK2's role in innate immune responses?

VRK2 plays a crucial role in antiviral innate immune responses, particularly in regulating mtDNA-triggered pathways . When investigating these functions:

• Viral infection models: The following experimental systems have been validated for VRK2 studies:

  • DNA viruses: HSV-1, MCMV

  • RNA viruses: EMCV, SeV

• Downstream signaling analysis: Monitor phosphorylation of key proteins in the pathway:

  • pSTING, pTBK1, and pIRF3 levels by Western blot (significantly inhibited in Vrk2−/− cells)

  • Type I interferon production (IFN-β) by ELISA or qPCR

• Cellular compartment analysis: Investigate VRK2's interaction with mitochondrial components:

  • Co-immunoprecipitation with VDAC1 to assess mtDNA regulation

  • Mitochondrial stress response elements

• In vivo validation: Compare wild-type and VRK2-deficient mice for:

  • Serum levels of IFN-β and CXCL10 after viral infection

  • Viral loads in target organs like brain tissue

  • Survival rates following viral challenge

When interpreting results, consider that VRK2's impact varies depending on virus type and cell type, with more pronounced effects observed for DNA viruses and certain RNA viruses like EMCV .

How can I effectively study VRK2's interactions with apoptotic regulators like Bcl-xL?

VRK2A modulates apoptosis through direct interaction with Bcl-xL and regulation of BAX expression . For studying these interactions:

• Proximity ligation assay (PLA): For detecting VRK2-Bcl-xL interactions in situ with spatial resolution

• Functional validation: Measure the following parameters when modulating VRK2 levels:

  • Cytochrome C release from mitochondria

  • Caspase activation and PARP processing

  • Annexin V+ cell populations by flow cytometry

  • BAX promoter activity using reporter assays

• Chemotherapeutic response: Assess sensitivity to apoptosis-inducing drugs like camptothecin or doxorubicin in cells with varying VRK2 expression levels

Research indicates that VRK2A specifically interacts with Bcl-xL but not with other apoptotic regulators like Bcl-2, Bax, Bad, PUMA, or Binp-3L, highlighting the specificity of this interaction .

What tissue and cell types exhibit significant VRK2 expression for antibody-based detection?

VRK2 exhibits variable expression patterns across tissues and cell types, which impacts detection sensitivity. For optimal antibody-based detection:

• High-expression tissues (recommended for positive controls):

  • Heart

  • Skeletal muscle

  • Pancreas

  • Testis

  • Fetal liver

  • Human liver

  • Human stomach

• Validated cell lines for reliable VRK2 detection:

  • HepG2

  • K-562

  • U2OS

  • BxPC-3

  • HEK-293T

• Primary cell systems validated for VRK2 studies:

  • Mouse lung fibroblasts (MLFs)

  • Bone marrow-derived macrophages (BMDMs)

When working with tissue samples, immunohistochemistry protocols may require optimization of antigen retrieval methods, with TE buffer (pH 9.0) showing superior results compared to citrate buffer (pH 6.0) for VRK2 epitope exposure .

What considerations are important when studying VRK2 in relation to neurological and psychiatric disorders?

VRK2 has been implicated in various neurological and psychiatric conditions, particularly schizophrenia (SCZ) and major depressive disorder . When investigating these connections:

• Genetic variation analysis: Consider SNPs with established associations:

  • rs2312147 (strong association with SCZ in Asian populations, p = 1.14 × 10–12)

  • rs1518395 (linkage disequilibrium with rs2312147 in East Asians)

• Brain region specificity: Examine VRK2 expression in neurologically relevant regions, as expression patterns may vary across brain structures

• Cell-type specificity: Consider neuronal vs. glial expression patterns when interpreting results

• Functional studies: Examine how disease-associated VRK2 variants affect:

  • Neuronal morphology

  • Signaling pathway alterations (particularly MAPK pathways)

  • Cellular stress responses

When reporting results, it's essential to consider the heterogeneity of psychiatric conditions and the potential for different mechanistic roles of VRK2 across various disorder subtypes .

How can I effectively study VRK2's role in MAPK signaling pathways?

VRK2 significantly regulates mitogen-activated protein kinase (MAPK) signaling, particularly in the context of EGF-ErbB2 pathways . For investigating these regulatory functions:

• Transcriptional reporter assays:

  • Serum response element (SRE)-driven luciferase reporters show dose-dependent inhibition by VRK2A

  • Recommended cell lines: HEK293T, MCF7, MDA-MB-231

• Oncogenic pathway investigation: Test VRK2's effects on constitutively active signaling components:

  • H-Ras(G12V)

  • B-Raf(V600E)

• Protein-protein interaction studies: Investigate VRK2's physical associations with MAPK pathway components using co-immunoprecipitation

• Clinical correlation: In breast cancer tissues, analyze the relationship between VRK2 and ErbB2 expression levels using immunohistochemistry on consecutive sections

The data show that high VRK2 levels inhibit EGF and ErbB2 activation of transcription, accompanied by reduced phosphorylated ERK levels, suggesting VRK2 functions as a negative regulator of this pathway .

What are the best experimental approaches to study subcellular localization of VRK2?

VRK2 exhibits distinct subcellular localization patterns essential to its function, with VRK2A (containing a C-terminal transmembrane domain) anchoring to organelle membranes while VRK2B localizes differently . To accurately investigate these patterns:

• Subcellular fractionation:

  • Separate nuclear, cytoplasmic, mitochondrial, and ER fractions

  • Use established markers to validate fraction purity

  • Analyze VRK2 distribution by Western blot

• Super-resolution microscopy: For precise spatial resolution of VRK2 at membrane interfaces

• Electron microscopy with immunogold labeling: For ultrastructural localization, particularly useful for membrane associations

• Live-cell imaging: Using tagged VRK2 constructs to monitor dynamic localization changes under various cellular conditions

When interpreting results, consider that certain fixation methods may disrupt membrane associations, potentially altering the apparent localization pattern of VRK2A. Additionally, overexpression systems may show artifactual distributions compared to endogenous protein .

What are common technical challenges when using VRK2 antibodies and how can they be addressed?

Researchers often encounter specific challenges when working with VRK2 antibodies. Evidence-based solutions include:

• Weak or absent signal in Western blots:

  • Increase protein loading (30-50 μg recommended for endogenous detection)

  • Optimize antibody concentration (1:500 as starting point)

  • Enhance detection with signal amplification systems

  • Use PVDF membranes instead of nitrocellulose for better protein retention

  • Extended primary antibody incubation (overnight at 4°C)

  • Verify expression levels in your cell type (see section 3.1 for high-expression systems)

• High background or non-specific bands:

  • More stringent blocking (5% BSA or milk, 1-2 hours)

  • Additional washing steps (5-6 times, 5-10 minutes each)

  • Antibody validation with knockout/knockdown controls

  • Pre-absorption with the immunizing peptide when available

  • Use of monoclonal antibodies for higher specificity

• Inconsistent immunoprecipitation results:

  • Optimize lysis conditions (non-denaturing buffers containing 1% NP-40)

  • Increase antibody amount (2-4 μg per sample)

  • Extended incubation time (overnight at 4°C with gentle rotation)

  • Pre-clear lysates to reduce non-specific binding

• Poor immunohistochemistry staining:

  • Optimize antigen retrieval (TE buffer pH 9.0 recommended)

  • Increase antibody concentration (1:50-1:100 for IHC)

  • Extended primary antibody incubation (overnight at 4°C)

  • Use biotin-streptavidin amplification systems

• Variability between experiments:

  • Standardize lysate preparation protocols

  • Include consistent positive controls

  • Prepare antibody aliquots to avoid freeze-thaw cycles

What controls are essential when studying VRK2 protein expression and function?

Proper experimental controls are critical for reliable VRK2 research. Essential controls include:

• Positive controls (validated systems with confirmed VRK2 expression):

  • Cell lines: HepG2, K-562, U2OS, BxPC-3, HEK-293T cells

  • Tissues: Human liver, mouse skeletal muscle, human stomach

• Negative controls:

  • VRK2 knockout or knockdown samples

  • Primary antibody omission control

  • Isotype control (matching IgG class and species)

  • Peptide competition (when immunizing peptide is available)

• Loading controls for Western blots:

  • Standard housekeeping proteins (GAPDH, β-actin, tubulin)

  • Consider compartment-specific controls for subcellular fractions:

    • Nuclear: Lamin B, Histone H3

    • Cytoplasmic: GAPDH, α-tubulin

    • Mitochondrial: VDAC, COX IV

    • ER: Calnexin, PDI

• Functional controls:

  • Positive controls for pathway activation (e.g., EGF stimulation for MAPK pathway)

  • Expected outcomes in well-characterized systems:

    • Reduced pERK levels with VRK2 overexpression

    • Decreased IFN-β production in VRK2-deficient cells after viral stimulation

    • Altered apoptotic response in VRK2-modulated systems

• Species reactivity controls:

  • Test antibody specificity across relevant species

  • Verify cross-reactivity claims with empirical testing

Implementing these comprehensive controls ensures reliable interpretation of experimental results and facilitates troubleshooting when unexpected outcomes occur.

What emerging research areas might benefit from advanced VRK2 antibody applications?

Several cutting-edge research directions show promise for VRK2 investigation:

• Single-cell analysis of VRK2 expression:

  • Application of VRK2 antibodies in mass cytometry (CyTOF)

  • Integration with single-cell transcriptomics

  • Spatial profiling in tissue microenvironments

• VRK2's role in mitochondrial stress responses:

  • Investigation of mtDNA release mechanisms

  • Interaction with VDAC1 oligomeric pores

  • Contribution to mitochondrial dynamics in neurological disorders

• Therapeutic targeting in psychiatric disorders:

  • Validation of VRK2 as a druggable target

  • Development of strategies to modulate specific VRK2 functions

  • Correlation of genetic variants with treatment responses

• Cancer biology applications:

  • VRK2's dual roles in tumor progression

  • Relationship with drug sensitivity

  • Prognostic value in specific cancer subtypes (e.g., astrocytomas)

• Mechanistic studies of post-translational modifications:

  • Identification of VRK2 substrates

  • Regulation of VRK2 activity through phosphorylation

  • Interplay with other kinase signaling networks

These emerging areas will benefit from continued refinement of antibody-based detection methods and their integration with complementary molecular and cellular techniques.

How can VRK2 antibodies be integrated with advanced imaging techniques for mechanistic studies?

Integration of VRK2 antibodies with cutting-edge imaging approaches offers new insights into protein function:

• Live-cell imaging optimization:

  • Conjugation of VRK2 antibody fragments with cell-permeable tags

  • Integration with optogenetic approaches

  • Multiplexed imaging with organelle-specific probes

• Expansion microscopy:

  • Physical expansion of specimens to resolve VRK2 localization at membranes

  • Compatibility with standard VRK2 antibodies

• Correlative light and electron microscopy (CLEM):

  • Precise ultrastructural localization of VRK2

  • Particularly valuable for membrane-associated VRK2A isoform

• Proximity labeling techniques:

  • BioID or APEX2 fusions with VRK2 to identify proximal interactors

  • Spatial mapping of VRK2 protein complexes

• Förster resonance energy transfer (FRET):

  • Investigation of VRK2 interactions with binding partners

  • Monitoring conformational changes upon activation

These advanced imaging applications will provide unprecedented insights into the subcellular dynamics and functional interactions of VRK2, particularly at membrane interfaces where traditional approaches have limitations.